Clinical effects of phosphodiesterase 3A mutations in inherited hypertension with brachydactyly

Hypertension

Volumn 66, Issue 4, 2015, Pages 800-808

  Toka, Okan ^a   Tank, Jens ^a   Schächterle, Carolin ^c   Aydin, Atakan ^c   Maass, Philipp G ^c,d,e   Elitok, Saban ^f   Bartels Klein, Eireen ^c   Hollfinger, Irene ^c   Lindschau, Carsten ^b,c,g   Mai, Knut ^c   Boschmann, Michael ^c   Rahn, Gabriele ^c   Movsesian, Matthew A ^h,i   Müller, Thomas ^j   Doescher, Andrea ^j   Gnoth, Simone ^j   Mühl, Astrid ^c   Toka, Hakan R ^k,l   Wefeld Neuenfeld, Yvette ^c   Utz, Wolfgang ^c,f   Töpper, Agnieszka ^c,f   Jordan, Jens ^b   Schulz Menger, Jeanette ^c,f   Klussmann, Enno ^c,m   Bähring, Sylvia ^c   Luft, Friedrich C ^c,n   more..

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d Harvard University   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f HELIOS Klinikum Berlin   (Germany)

^g Staatliche Technikerschule Berlin   (Germany)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j Blood Transfusion Center   (Germany)

^k EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^l Hampton VA Medical Center   (United States)

^m DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

ⁿ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

blood platelets; brachydactyly; cyclic nucleotide phosphodiesterases; genetics; HTNB; hypertension; type 3

Indexed keywords

CILOSTAZOL; CYCLIC AMP; CYCLIC GMP; MILRINONE; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IIIA; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; DNA;

ADOLESCENT; ADULT; ARTICLE; BRACHYDACTYLY; CARDIOVASCULAR MAGNETIC RESONANCE; CELL FRACTIONATION; CELL PROLIFERATION; CENTRAL DIASTOLIC BLOOD PRESSURE; CENTRAL SYSTOLIC BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; ECHOCARDIOGRAPH; ENZYME PHOSPHORYLATION; FEMALE; FOUR DIMENSIONAL ECHOCARDIOGRAPHY; GENE MUTATION; HAND GRIP; HEART FUNCTION; HUMAN; HUMAN CELL; HYPERTENSION; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; YOUNG ADULT; BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; ENZYMOLOGY; GENETICS; IMMUNOBLOTTING; METABOLISM; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ADOLESCENT; ADULT; BLOOD PRESSURE; BRACHYDACTYLY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DNA; DNA MUTATIONAL ANALYSIS; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; HUMANS; HYPERTENSION; IMMUNOBLOTTING; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 84941219846     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06000     Document Type: Article

References (52)

1. Padmanabhan S, Caulfield M, Dominiczak AF, Genetic and molecular aspects of hypertension. Circ Res 2015 116 937 959. doi: 10.1161/CIRCRESAHA.116.303647
2. Lifton RP, Genetic dissection of human blood pressure variation: common pathways from rare phenotypes. Harvey Lect 2004 100 71 101
3. Toka HR, Koshy JM, Hariri A, The molecular basis of blood pressure variation. Pediatr Nephrol 2013 28 387 399. doi: 10.1007/s00467-012-2206-9
4. Bilginturan N, Zileli S, Karacadag S, Pirnar T, Hereditary brachydactyly associated with hypertension. J Med Genet 1973 10 253 259
5. Schuster H, Wienker TF, Toka HR, Bähring S, Jeschke E, Toka O, Busjahn A, Hempel A, Tahlhammer C, Oelkers W, Kunze J, Bilginturan N, Haller H, Luft FC, Autosomal dominant hypertension and brachydactyly in a Turkish kindred resembles essential hypertension. Hypertension 1996 28 1085 1092
6. Jordan J, Toka HR, Heusser K, Toka O, Shannon JR, Tank J, Diedrich A, Stabroth C, Stoffels M, Naraghi R, Oelkers W, Schuster H, Schobel HP, Haller H, Luft FC, Severely impaired baroreflex-buffering in patients with monogenic hypertension and neurovascular contact. Circulation 2000 102 2611 2618
7. Bähring S, Rauch A, Toka O, Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12. Hypertension 2004 43 471 476. doi: 10.1161/01.HYP.0000111808.08715.ec
8. Bähring S, Kann M, Neuenfeld Y, Gong M, Chitayat D, Toka HR, Toka O, Plessis G, Maass P, Rauch A, Aydin A, Luft FC, Inversion region for hypertension and brachydactyly on chromosome 12p features multiple splicing and noncoding RNA. Hypertension 2008 51 426 431. doi: 10.1161/HYPERTENSIONAHA.107.101774
9. McEniery CM, Yasmin, Maki-Petaja KM, McDonnell BJ, Munnery M, Hickson SS, Franklin SS, Cockcroft JR, Wilkinson IB, Anglo-Cardiff Collaboration Trial Investigators The impact of cardiovascular risk factors on aortic stiffness and wave reflections depends on age: the Anglo-Cardiff Collaborative Trial (ACCT III). Hypertension 2010 56 591 597. doi: 10.1161/HYPERTENSIONAHA.110.156950
10. Schuster H, Wienker TE, Bähring S, Bilginturan N, Toka HR, Neitzel H, Jeschke E, Toka O, Gilbert D, Lowe A, Ott J, Haller H, Luft FC, Severe autosomal dominant hypertension and brachydactyly in a unique Turkish kindred maps to human chromosome 12. Nat Genet 1996 13 98 100. doi: 10.1038/ng0596-98
11. Toka HR, Bähring S, Chitayat D, Melby JC, Whitehead R, Jeschke E, Wienker TF, Toka O, Schuster H, Luft FC, Families with autosomal dominant brachydactyly type E, short stature, and severe hypertension. Ann Intern Med 1998 129 204 208
12. Gong M, Zhang H, Schulz H, Lee YA, Sun K, Bähring S, Luft FC, Nürnberg P, Reis A, Rohde K, Ganten D, Hui R, Hübner N, Genome-wide linkage reveals a locus for human essential (primary) hypertension on chromosome 12p. Hum Mol Genet 2003 12 1273 1277
13. Simino J, Sung YJ, Kume R, Schwander K, Rao DC, Gene-Alcohol interactions identify several novel blood pressure loci including a promising locus near SLC16A9. Front Genet 2013 4 277. doi: 10.3389/fgene.2013.00277
14. Maass PG, Aydin A, Luft FC, PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet 2015 47 647 653. doi: 10.1038/ng.3302
15. Conti M, Beavo J, Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007 76 481 511. doi: 10.1146/annurev.biochem.76.060305.150444
16. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo SL, Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003 64 533 546. doi: 10.1124/mol.64.3.533
17. Toka O, Maass PG, Aydin A, Toka H, Hübner N, Rüschendorf F, Gong M, Luft FC, Bähring S, Childhood hypertension in autosomal-dominant hypertension with brachydactyly. Hypertension 2010 56 988 994. doi: 10.1161/HYPERTENSIONAHA.110.156620
18. Schuster H, Toka O, Toka HR, Busjahn A, Oztekin O, Wienker TF, Bilginturan N, Bähring S, Skrabal F, Haller H, Luft FC, A cross-over medication trial for patients with autosomal-dominant hypertension with brachydactyly. Kidney Int 1998 53 167 172. doi: 10.1046/j.1523-1755.1998.00732.x
19. Hattenbach LO, Toka HR, Toka O, Schuster H, Luft FC, Absence of hypertensive retinopathy in a Turkish kindred with autosomal dominant hypertension and brachydactyly. Br J Ophthalmol 1998 82 1363 1365
20. Colman RW, Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis. Semin Thromb Hemost 2004 30 451 460. doi: 10.1055/s-2004-833480
21. Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T, Oscillometric estimation of aortic pulse wave velocity: comparison with intra-Aortic catheter measurements. Blood Press Monit 2013 18 173 176. doi: 10.1097/MBP.0b013e3283614168
22. Wassertheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M, Hametner B, Mayer CC, Eber B, Magometschnigg D, A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypertens 2010 24 498 504. doi: 10.1038/jhh.2010.27
23. Lang RM, Badano LP, Mor-Avi V, Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015 28 1 39.e14. doi: 10.1016/j.echo.2014.10.003
24. Quiñones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA, Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002 15 167 184
25. Kuecherer HF, Just A, Kirchheim H, Evaluation of aortic compliance in humans. Am J Physiol Heart Circ Physiol 2000 278 H1411 H1413
26. Grotenhuis HB, Westenberg JJ, Steendijk P, van der Geest RJ, Ottenkamp J, Bax JJ, Jukema JW, de Roos A, Validation and reproducibility of aortic pulse wave velocity as assessed with velocity-encoded MRI. J Magn Reson Imaging 2009 30 521 526. doi: 10.1002/jmri.21886
27. von Knobelsdorff-Brenkenhoff F, Dieringer MA, Fuchs K, Hezel F, Niendorf T, Schulz-Menger J, Isometric handgrip exercise during cardiovascular magnetic resonance imaging: set-up and cardiovascular effects. J Magn Reson Imaging 2013 37 1342 1350. doi: 10.1002/jmri.23924
28. Vandeput F, Szabo-Fresnais N, Ahmad F, Kho C, Lee A, Krall J, Dunlop A, Hazel MW, Wohlschlegel JA, Hajjar RJ, Houslay MD, Manganiello VC, Movsesian MA, Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms. Proc Natl Acad Sci U S A 2013 110 19778 19783. doi: 10.1073/pnas.1305427110
29. Ahmad F, Shen W, Vandeput F, Szabo-Fresnais N, Krall J, Degerman E, Goetz F, Klussmann E, Movsesian M, Manganiello V, Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2. J Biol Chem 2015 290 6763 6776. doi: 10.1074/jbc.M115.638585
30. Grant PG, Mannarino AF, Colman RW, cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A 1988 85 9071 9075
31. Simpson AW, Reeves ML, Rink TJ, Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem Pharmacol 1988 37 2315 2320
32. Hadrava V, Tremblay J, Hamet P, Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension 1989 13 6 Pt 1 589 597
33. Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, Tulis DA, The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J Pharmacol Exp Ther 2011 339 394 402. doi: 10.1124/jpet.111.183400
34. Folkow B, Hypertensive structural changes in systemic precapillary resistance vessels: how important are they for in vivo haemodynamics? J Hypertens 1995 13 12 Pt 2 1546 1559
35. DiBona GF, Mark AL, Björn Folkow. Hypertension 2013 61 4
36. Murata T, Shimizu K, Hiramoto K, Tagawa T, Phosphodiesterase 3 (PDE3): structure, localization and function. Cardiovasc Hematol Agents Med Chem 2009 7 206 211
37. Francis SH, Busch JL, Corbin JD, Sibley D, cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010 62 525 563. doi: 10.1124/pr.110.002907
38. Kurtz TW, Dominiczak AF, DiCarlo SE, Pravenec M, Morris RC Jr, Molecular-based mechanisms of Mendelian forms of salt-dependent hypertension: questioning the prevailing theory. Hypertension 2015 65 932 941. doi: 10.1161/HYPERTENSIONAHA.114.05092
39. Sunagawa K, Sagawa K, Maughan WL, Ventricular interaction with the loading system. Ann Biomed Eng 1984 12 163 189
40. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K, Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 1983 245 5 Pt 1 H773 H780
41. Chen CH, Fetics B, Nevo E, Rochitte CE, Chiou KR, Ding PA, Kawaguchi M, Kass DA, Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol 2001 38 2028 2034
42. Ghigo A, Perino A, Mehel H, Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 2012 126 2073 2083. doi: 10.1161/CIRCULATIONAHA.112.114074
43. Oikawa M, Wu M, Lim S, Knight WE, Miller CL, Cai Y, Lu Y, Blaxall BC, Takeishi Y, Abe J, Yan C, Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol 2013 64 11 19. doi: 10.1016/j.yjmcc.2013.08.003
44. Iwaya S, Oikawa M, Chen Y, Takeishi Y, Phosphodiesterase 3A1 protects the heart against angiotensin II-induced cardiac remodeling through regulation of transforming growth factor-β expression. Int Heart J 2014 55 165 168
45. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991 325 1468 1475. doi: 10.1056/NEJM199111213252103
46. Laflamme M, Perrault LP, Carrier M, Elmi-Sarabi M, Fortier A, Denault AY, Preliminary experience with combined inhaled milrinone and prostacyclin in cardiac surgical patients with pulmonary hypertension. J Cardiothorac Vasc Anesth 2015 29 38 45. doi: 10.1053/j.jvca.2014.06.012
47. Hunter RW, Mackintosh C, Hers I, Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem 2009 284 12339 12348. doi: 10.1074/jbc.M807536200
48. Michael SK, Surks HK, Wang Y, Zhu Y, Blanton R, Jamnongjit M, Aronovitz M, Baur W, Ohtani K, Wilkerson MK, Bonev AD, Nelson MT, Karas RH, Mendelsohn ME, High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci U S A 2008 105 6702 6707. doi: 10.1073/pnas.0802128105
49. Stasch JP, Pacher P, Evgenov OV, Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011 123 2263 2273. doi: 10.1161/CIRCULATIONAHA.110.981738
50. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C, CHEST-1 Study Group Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013 369 319 329. doi: 10.1056/NEJMoa1209657
51. Wiesner S, Birkenfeld AL, Engeli S, Haufe S, Brechtel L, Wein J, Hermsdorf M, Karnahl B, Berlan M, Lafontan M, Sweep FC, Luft FC, Jordan J, Neurohumoral and metabolic response to exercise in water. Horm Metab Res 2010 42 334 339. doi: 10.1055/s-0030-1248250
52. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP, Blood-pressure reduction with LCZ696, a novel dual-Acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010 375 1255 1266. doi: 10.1016/S0140-6736(09)61966-8